Clinical value of detecting autoantibodies against β-, β,- and α-adrenergic receptors in carvedilol treatment of patients with heart failure.

OBJECTIVE

To determine the possible association of anti-β-adrenergic receptors (anti-β-AR), anti-β-AR and anti-α-AR with carvedilol treatment in patients with heart failure (HF).

METHODS

A total of 267 HF patients were prospectively enrolled. Blood samples were measured by an enzyme-linked immunosorbent assay. All of the patients received carvedilol for their HF. Each patient was followed up for six months and their cardiac function was measured.

RESULTS

The final analysis encompassed 137 patients comprising 65 patients with three autoantibodies (positive group) and 72 patients without all three autoantibodies but with one or two autoantibodies (negative group). The frequency and geometric mean titer of anti-β-AR, anti-β-AR, and anti-α-AR were significantly lower in the group without all three autoantibodies after six months of carvedilol treatment (all < 0.01; from 100% to 57%, 50%, and 49%, respectively; and from 1: 118, 1: 138, and 1: 130 to 1: 72, 1: 61, and 1: 67, respectively). Furthermore, 28 patients in the positive group demonstrated complete ablation of autoantibodies. In addition, left ventricular remodelling and function was significantly improved by the use of carvedilol combined with the standard treatment regime for six months in the positive group ( < 0.01) when compared to the negative group ( < 0.05).

CONCLUSIONS

Carvedilol treatment significantly decreases frequency and geometric mean titer in patients with all three autoantibodies, even up to complete ablation, and significantly improved cardiac function and remodelling. The effect of carvedilol is probably correlated to the presence of all three autoantibodies.